신생아 발병 OTC 결핍증(OTC-HOPE)이 있는 생후 9개월 미만 남자 아기에서 ECUR-506을 조사하기 위한 공개 라벨 연구
유전적으로 확인된 신생아 발병이 있는 9개월 미만 남성을 대상으로 ECUR-506의 단일 정맥(IV) 투여의 안전성과 유효성을 평가하기 위한 최초의 인간 대상 공개 라벨 용량 증량 연구 오르니틴 트랜스카바밀라제(OTC) 결핍
Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for detoxifying of ammonia. Individuals with OTC deficiency can develop elevated levels of ammonia in the blood, potentially resulting in severe consequences, including cumulative and irreversible neurological damage, coma, and death. The most severe form presents shortly after birth and occurs more commonly in boys than girls.
This is a Phase 1/2/3, open-label, multicenter study evaluating the safety, efficacy, and dose of ECUR-506 in male babies with neonatal-onset OTC deficiency. The primary objective is to evaluate the safety, tolerability, and efficacy of up to three dose levels of ECUR-506 following intravenous (IV) administration of a single dose.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The study drug, ECUR-506, is an investigational gene editing therapy. Gene editing is an approach used to repair, replace, or introduce functional copies of genes that are not working properly. ECUR-506 contains a functional copy of the OTC gene, along with a gene to encode an editing enzyme that enables insertion of the OTC gene into the genome. The study drug is administered as a single IV infusion. Because genes cannot enter cells on their own, ECUR-506 uses a delivery system based on adeno-associated virus (AAV), a commonly used viral vector, to transport the genetic material into cells.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 장소
-
-
California
-
Los Angeles, California, 미국, 90095
- UCLA Mattel Children's Hospital
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- Children's Hospital of Colorado, Anshutz Medical Campus
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Emory University School of Medicine
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
New York
-
New York, New York, 미국, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- Oregon Health and Science University
-
-
-
-
-
Barcelona, 스페인, 08950
- Hopsital Sant Joan de Deu
-
Madrid, 스페인, 28041
- Hospital Universitario 12 de Octubre
-
-
-
-
-
London, 영국
- Great Ormond Street Hospital
-
Newcastle upon Tyne, 영국
- The Newcastle upon Tyne Hospitals NHS Foundation Trust- Great North Children's Hospital
-
-
-
-
New South Wales
-
Sydney, New South Wales, 호주
- The Children's Hospital at Westmead
-
-
Victoria
-
Melbourne, Victoria, 호주, 3052
- The Royal Children's Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Male sex
- Gestational or adjusted (corrected) gestational age ≥ 37 weeks
- Age at screening is 24 hours to 7 months
- Weight ≥ 3.5 kg and ≤ 13.5 kg at screening
- Has received age-appropriate vaccinations
- Genetically confirmed OTCD defined by genetic confirmation of an OTC variant (pathogenic or likely pathogenic) associated with severe neonatal OTCD defined below in Inclusion Criteria #7 or has the same OTC variant as a family member who had severe neonatal OTCD within first week of life.
- Severe neonatal OTCD defined by hyperammonemic crisis with elevated ammonia level of >560 μmol/L and clinical symptoms within first week of life, and currently receiving treatment with both dietary protein restriction and nitrogen scavenger therapy.
- Current or historical biochemical profile consistent with OTCD
- Participant's parent(s)/LAR must be able to comprehend and be willing to provide a signed IRB/IEC-approved ICF.
Key Exclusion Criteria:
- Neonatal diagnosis of severe to profound Hypoxic Ischemic Encephalopathy due to birth injury
- Requiring urgent liver transplant due to liver failure as assessed by the PI.
- Contiguous gene deletion involving the OTC gene and including at least the CYBB gene on the telomeric side or the TSPAN7 gene on the centromeric side.
- Known or suspected major organ injury/dysfunction/anomalies.
- Vital sign and laboratory abnormalities outside of reference ranges.
- Treatment with any other gene therapy or gene editing therapy
- Co-enrollment in any other study unless approved by the sponsor.
- Any condition, that in the opinion of the Investigator, would compromise the safety of the participant or study data
- Documented vertical transmission of HepA/HepB/HepC
- Documented in-utero teratogen, substance, and/or alcohol exposure, which in the opinion of the Investigator may increase the participant's risk of developmental delays, congenital anomalies, and/or significant medical complications
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Low Dose Level
Participants will receive the Low Dose of ECUR-506 delivered one time via IV Infusion. |
ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene. |
|
실험적: Intermediate Dose Level
Participants will receive an intermediate dose of ECUR-506 delivered on time via IV infusion |
ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene. |
|
실험적: High Dose Level
Participants will receive a higher dose of ECUR-506 delivered one time via IV infusion. |
ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Treatment-emergent adverse events (incidence, severity, seriousness, and relatedness)
기간: Over 24 weeks post infusion
|
Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events (AEs) are reported based on clinical laboratory tests, vital signs, physical examinations, Pediatric Neurologist exam parameters, electrocardiograms, and any other medically indicated assessments from the time informed consent is signed through the end of the safety follow-up period. AEs are considered to be treatment emergent (TEAE) if they occur or worsen in severity following the administration of the study treatment. TEAEs are considered treatment-related if relationship to study drug is possibly related, probably related, or definitely related. |
Over 24 weeks post infusion
|
|
Physical exam parameters
기간: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Includes PI assessment of General Appearance, Dermatological, HEENT, Lymphatic, Respiratory, Cardiovascular, Gastrointestinal, Musculoskeletal, Neurological (Cranial Nerve Function, Motor System Function, Sensory System Function, Primitive Reflexes)) |
Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Vital sign parameters
기간: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Includes PI assessment of Systolic Blood Pressure, Diastolic Blood Pressure, Pulse Rate, Respiratory Rate, Temperature) |
Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Pediatric neurologist exam parameters
기간: Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Includes Pediatric Neurologist assessment of Neurological status by review of Cranial Nerve Function, Motor System Function, Sensory System Function, Primitive Reflexes.) |
Assessed as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Blood safety tests including hematology, serum chemistry, liver function tests, coagulation tests
기간: as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Blood Safety tests to be reviewed in relation to established normal ranges for each assessment for the applicable age group) |
as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Urinalysis evaluations
기간: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events (AEs) are reported based on clinical laboratory tests, vital signs, physical examinations, electrocardiograms, and any other medically indicated assessments from the time informed consent is signed through the end of the safety follow-up period. AEs are considered to be treatment emergent (TEAE) if they occur or worsen in severity following the administration of the study treatment. TEAEs are considered treatment-related if relationship to study drug is possibly related, probably related, or definitely related. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
12 lead ECG parameters
기간: as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
Safety- (Includes PI review of Heart Rate, PR Interval, RR Interval, QRS Duration, QT Interval, QTcF Interval, Overall Interpretation) |
as change from baseline at pre-specified timepoints as described in the SOE throughout the duration of the study on all enrolled and dosed participants.
|
|
Complete clinical response
기간: Over 24 weeks post infusion
|
Discontinuation of scavenger medication for a minimum duration of 28 days without reductions in prescribed daily protein intake during this time period by end of study. |
Over 24 weeks post infusion
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of HAEs/person-year
기간: Day 1 post dose through Week 24
|
Key Secondary Endpoint: Pharmacodynamics and Efficacy |
Day 1 post dose through Week 24
|
|
qPCR measurement to evaluate the clearance of both vectors in body fluids over time
기간: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacokinetics |
Over 24 weeks post infusion
|
|
Incidence of hyperammonemic episode (HAE)
기간: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy |
Over 24 weeks post infusion
|
|
Incidence and number of hyperammonemic episodes (HAE/HAC) resulting in hospitalization
기간: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy |
Over 24 weeks post infusion
|
|
Overall and by hospitalization severity (Mild: adjustment of dietary protein intake and oral scavenger medication / Moderate: cessation of dietary protein intake and initiation of IV scavenger therapy / Severe: requirement for hemodialysis)
기간: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy. |
Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants
|
|
Duration of hospitalization for each HAE/HAC
기간: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy |
Over 24 weeks post infusion
|
|
Requirement for Intensive Care Unit (ICU) care during hospitalization for each HAE/HAC
기간: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics and Efficacy |
Over 24 weeks post infusion
|
|
Time to liver transplant from dosing to end of study (EOS)
기간: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Supportive Secondary Endpoint: Efficacy |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Transplant free survival
기간: Time to lever transplant or any-cause death from dosing to EOS
|
Supportive Secondary Endpoint: Efficacy |
Time to lever transplant or any-cause death from dosing to EOS
|
|
Overall survival
기간: Time to any-cause death from dosing to EOS
|
Supportive Secondary Endpoint: Efficacy |
Time to any-cause death from dosing to EOS
|
|
Achieving and maintaining complete clinical response through end of study
기간: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Efficacy |
Over 24 weeks post infusion
|
|
Scavenger drug dose
기간: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Efficacy |
Over 24 weeks post infusion
|
|
Dietary protein intake g/kg/day
기간: Supportive Secondary: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Efficacy |
Supportive Secondary: Over 24 weeks post infusion
|
|
Blood urea nitrogen measurements
기간: Over 24 weeks post infusion
|
Supportive Secondary Endpoint: Pharmacodynamics |
Over 24 weeks post infusion
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Clinical Response (CR) defined as reduction in baseline standard of care therapy
기간: Assessed at Week 24
|
Efficacy |
Assessed at Week 24
|
|
Serum Neurofilament Light Chain
기간: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Safety |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Number of participants with antibodies to AAVrh79 capsid in blood
기간: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Number of participants with antibodies to hOTC transgene in blood
기간: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Number of participants with antibodies to M2PCSK9 transgene in blood
기간: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Incidence and time to medical management adjustments based on iECURE guidance (protein diet or scavenger medication)
기간: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Efficacy |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Fasting plasma ammonia
기간: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Fasting plasma citrulline and fasting plasma glutamine levels
기간: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Serum PCSK9
기간: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Pharmacodynamics |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Urinary excretion of phenylacetate metabolites
기간: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Urinary phenylacetate (mcg/mL), urinary phenylacetylglutamine (mcg/mL), urinary phenylacetate/ phenylglutamine ratio. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Urinary excretion of orotic acid metabolites.
기간: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Urinary orotic acid (mmol/ mol creatinine), urinary uracil (mmol/mol creatinine). |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Urinary nitrogen to urinary creatinine ratio.
기간: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Urinary nitrogen to urinary creatinine ratio (mg/dL) |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Change from baseline at Week 24 post infusion in length.
기간: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Length measured in centimeters. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Change from baseline at Week 24 post infusion in weight.
기간: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Weight measured in kilograms. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Percent liver transduction via ISH/IF (in-situ hybridization / Immunofluorescence)"at Wk 24 collected by liver biopsy.
기간: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
Pharmacodynamics |
The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
|
Assess the potential on and "off" target editing by amplicon-seq in liver tissue samples of participants who received ECUR-506.
기간: The following will be assessed at week 24 if liver biopsy tissue sample is sufficient.
|
Pharmacodynamics |
The following will be assessed at week 24 if liver biopsy tissue sample is sufficient.
|
|
Assess potential off-target editing with AAV vector ITR insertion by ITR-seq in liver tissue samples of participants who received ECUR-506
기간: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
Pharmacodynamics |
The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
|
Assess for potential genetic changes in the liver tissue, collected by liver biopsy, through long read sequencing, in participants who have received ECUR-506
기간: The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
Pharmacodynamics |
The following will be assessed at Week 24 if liver biopsy tissue sample is sufficient.
|
|
With an observed genetic safety signal, genetic analysis of Whole Blood DNA may be performed on samples collected and stored at screening and week 24, in the event of an observed genomic safety signal.
기간: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
|
Safety |
Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
|
|
Change from baseline at Week 24 post infusion in Bayley Scales of Infant and Toddler Development 4th Ed (BSID-4) for the Cognitive, Language, and Motor scales
기간: Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
Total Raw Scores, Growth Score Values (GSVs), and Age Equivalent Scores will be analyzed; Raw Scores range 0-162; GSVs range 428-599; Age Equivalent Scores range 1-42 months; a higher score reflects a higher level of skill. |
Assessed as change from baseline at pre-specified timepoints through Week 24 post infusion.
|
|
Quality of Life, as measured by the Pediatric QOL inventory Infant Scale (PedsQL-IS)
기간: Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
|
Quality of Life |
Will be assessed Day 1 post dose through Wk 24 on all enrolled and dosed participants.
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: George Diaz, M.D., Ph.D, iECURE, Inc.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- ECUR-506-OTC-101
- OTC-HOPE (기타 식별자: iECURE, Inc.)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .